Prevention of infectious complications after transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone

Hepato-Gastroenterology

Volumn 46, Issue 26, 1999, Pages 1126-1130

  Gulberg, Veit ^a   Deibert, Peter ^b   Ochs, Andreas ^b   Rossle, Martin ^b   Gerbes, Alexander L ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Antibiotic prophylaxis; Ceftriaxone; Cirrhosis; Infections; TIPS

Indexed keywords

C REACTIVE PROTEIN; CEFTRIAXONE; CEPHALOSPORIN; IMIPENEM;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBIOTIC PROPHYLAXIS; CEFTRIAXONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 0032961276     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 1 Caly WR, Strauss E: A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353-358.
2. 2 Casafont Morencos F, de las Heras Castano G, Martin Ramos L, Lopez Arias M, Ledesma F, Pons Romero F: Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996; 41:552-556.
3. 3 Holdstock G, Leslie B, Hill S, Tanner A, Wright R: Monocyte function in cirrhosis. J Clin Pathol 1982; 35:972-979.
4. 4 Gomez F, Ruiz P, Schreiber AD: Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331:1122-1128.
5. 5 O'Keefe SJ, El Zayadi AR, Carraher TE, Davis M, Williams R: Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980; 2:615-617.
6. 6 Rolando N, Gimson A, Philpott HJ, Sahathevan M, Casewell M, Pagan E, Westaby D, Williams R: Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993; 18:290-294.
7. 7 Gerhartz HH, Sauerbruch T, Weinzierl M, Ruckdeschel G: Nosocomial septicemia in patients undergoing sclerotherapy for variceal hemorrhage. Endoscopy 1984; 16:129-130.
8. 8 Schiano TD, Atillasoy E, Fiel MI, Wolf DC, Jaffe D, Cooper JM, Jonas ME, Bodenheimer-HC J, Min AD: Fatal fungemia resulting from an infected transjugular intrahepatic portosystemic shunt stent. Am J Gastroenterol 1997; 92:709-710.
9. 9 Blum U, Rossle M, Haag K, Ochs A, Blum HE, Hauenstein KH, Astinet F, Langer M: Budd-Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology 1995; 197:805-811.
10. 10 Rousseau H, Vinel JP, Bilbao JI, Longo JM, Maquin P, Zozaya JM, Garcia VL, Coustet B, Railhac N, Railhac JJ, et al: Transjugular intrahepatic portosystemic shunts using the Wallstent prosthesis: a follow-up study. Cardiovasc Intervent Radiol 1994; 17:7-11.
11. 11 Deibert P, Schwarz S, Olschewski M, Siegerstetter V, Blum HE, Rossle M: Risk factors and prevention of early infection after implantation of transjugular intrahepatic portosystemic shunts: results of a randomized study. Dig Dis Sci 1998; 43:1708-1713.
12. 12 Stanley AJ, Jalan R, Forrest EH, Redhead DN, Hayes PC: Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients. Gut 1996; 39:479-485.
13. 13 Sanyal AJ, Freedman AM, Luketic VA, Purdum PP, Shiffman ML, Cole PE, Tisnado J, Simmons S: Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:849-857.
14. 14 Yuk JH, Nightingale CH, Quintiliani R: Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet 1989; 17:223-235.
15. 15 Ross CB, Wheeler WG, Jones MJ, Kerins CA, Peek TE: Ceftriaxone versus cefazolin in peripheral arterial operations: a randomized, prospective trial. South Med J 1997; 90:16-22.
16. 16 Weaver M, Burdon DW, Youngs DJ, Keighley MR: Oral neomycin and erythromycin compared with single-dose systemic metronidazole and ceftriaxone prophylaxis in elective colorectal surgery. Am J Surg 1986; 151:437-442.
17. 17 Kellum-JM J, Gargano S, Gorbach SL, Talcof C, Curtis LE, Weiner B, McCoobery M, Tan JS, Kelly T, Wagner D, et al: Antibiotic prophylaxis in high-risk biliary operations: multicenter trial of single preoperative ceftriaxone versus multidose cefazolin. Am J Surg 1984; 148:15-18.
18. 18 Kreter B, Woods M: Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992; 104:590-599.
19. 19 Mercader J, Gomez J, Ruiz J, Garre MC, Valdes M: Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy 1989; 35(Suppl 2):23-26.
20. 20 Mesquita MA, Balbino EP, Albuquerque RS, Carmona CA, Okubo BT, Lorena SL, Montes CG, Soares EC: Ceftriaxone in the treatment of spontaneous bacterial peritonitis: ascitic fluid polymorphonuclear count response and short-term prognosis. Hepato-Gastroenterol 1997; 44:1276-1280.
21. 21 Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, Berger E, Blum U, Gabelmann A, Hauenstein K, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330:165-171.
22. 22 Conn HO: Transjugular intrahepatic portal-systemic shunts: the state of the art. Hepatol 1993; 17:148-158.
23. 23 Mandell GL, Sande MA: Antimicrobial agents: penicillins, cephalosporins, and other beta-lactam antibiotics. In: Gilman AG, Rall TW, Nies AS, Taylor P (Eds.). Goodman and Gilman's the pharmacological basis of therapeutics. New York, MacGraw-Hill, 1993; pp. 1065-1097.